When Does Mirati Therapeutics Inc. (MRTX) Become A Good Investment?
Mirati Therapeutics Inc. (NASDAQ:MRTX) has a beta value of 1.39 and has seen 0.29 million shares traded in the last trading session. The company, currently valued at $8.56B, closed the last trade at $167.59 per share which meant it gained $1.15 on the day or 0.69% during that session. The MRTX stock price is -48.83% off its 52-week high price of $249.42 and 34.26% above the 52-week low of $110.17. The 3-month trading volume is 598.71K shares. The consensus among analysts is that Mirati Therapeutics Inc. (MRTX) is an Overweight stock at the moment, with a recommendation rating of 2.10. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 3 out of 13 have rated it as a Hold, with 9 advising it as a Buy. 1 have rated the stock as Underweight. Mirati Therapeutics Inc. (NASDAQ:MRTX) trade information  Sporting 0.69% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Friday, 07/02/21 when the MRTX stock price touched $167.59 or saw a rise of 4.56%. Year-to-date, Mirati Therapeutics Inc. shares have moved -23.70%, while the 5-day performance has seen it change 2.01%. Over the past 30 days, the shares of Mirati Therapeutics Inc. (NASDAQ:MRTX) have changed 8.22%. Wall Street analysts have a consensus price target for the stock at $225.90, which means that the shares value could jump 25.81% from current levels. The projected low price target is $160.00 while the price target rests at a high of $300.00. In that case, then, we find that the current price level is -79.01% off the targeted high while a plunge would see the stock lose 4.53% from current levels. Mirati Therapeutics Inc. (MRTX) estimates and forecasts  Figures show that Mirati Therapeutics Inc. shares have underperformed across the wider relevant industry. The companys shares have lost -23.70% over the past 6 months, with this year growth rate of -28.77%, compared to 8.40% for the industry. If we evaluate the companys growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -15.80% over the past 5 years. MRTX Dividends  Mirati Therapeutics Inc. is expected to release its next earnings report in August this year, and investors are excited at the prospect of better dividends despite the companys debt issue.